Christian Rask-Madsen

Christian Rask-Madsen

Auto-generated profile, based on publicly available information

Christian Rask-Madsen

Joslin Diabetes Center and Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Cell Metabolism
Verified
Journal Article
Closed access
CRChristian Rask-Madsen
Christian Rask-Madsen
GKGeorge L. King
George L. King

1 February 2008 in Cell Metabolism
Verified
Journal Article
Closed access
SBSudha B. Biddinger
Sudha B. Biddinger
AHAntonio Hernandez-Ono
Antonio Hernandez-Ono
CRChristian Rask-Madsen
Christian Rask-Madsen
JHJoel T. Haas
Joel T. Haas
JAJose Orlando Aleman
Jose Orlando Aleman
CKC. Ronald Kahn
C. Ronald Kahn

1 January 2007 in Nature Clinical Practice Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
CRChristian Rask-Madsen
Christian Rask-Madsen
GKGeorge L King
George L King

1 September 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
CRChristian Rask-Madsen
Christian Rask-Madsen
CKC. Ronald Kahn
C. Ronald Kahn
Impaired insulin signaling is central to development of the metabolic syndrome and can promote cardiovascular disease indirectly through development of abnormal glucose and lipid metabolism, hypertension, and a proinflammatory state. However, insulin’s action directly on vascular endothelium, atherosclerotic plaque macrophages, and in the heart, kidney, and retina has now been described, and impaired insulin signaling in these locations can alter progression of cardiovascular disease in the metabolic syndrome and affect development of microvascular complications of diabetes mellitus. Recent advances in our understanding of the complex pathophysiology of insulin’s effects on vascular tissues offer new opportunities for preventing these cardiovascular disorders.

1 May 2010 in Cell Metabolism
Verified
Journal Article
Closed access
CRChristian Rask-Madsen
Christian Rask-Madsen
QLQian Li
Qian Li
BFBryn Freund
Bryn Freund
DFDanielle Feather
Danielle Feather
RARoman Abramov
Roman Abramov
GKGeorge L. King
George L. King

20 October 2005 in Journal of Vascular Research
Verified
Journal Article
Closed access
PDF file
HDHelena Dominguez
Helena Dominguez
HSHeidi Storgaard
Heidi Storgaard
CRChristian Rask-Madsen
Christian Rask-Madsen
THThomas Steffen Hermann
Thomas Steffen Hermann
NINikolaj Ihlemann
Nikolaj Ihlemann
CTChristian Torp-Pedersen
Christian Torp-Pedersen
Objective: The pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) impairs insulin action in insulin-sensitive tissues, such as fat, muscle and endothelium, and causes endothelial dysfunction. We hypothesized that TNF-α blockade with etanercept could reverse vascular and metabolic insulin resistance. Method and Results: Twenty obese patients with type 2 diabetes were randomized to etanercept treatment (25 mg subcutaneously twice weekly for 4 weeks) or used as controls in an open parallel study. Forearm blood flow and glucose uptake were measured during intra-arterial infusions of serotonin, sodium nitroprusside and insulin co-infused with serotonin. β-Cell function was assessed with oral and intra-venous glucose tolerance tests and whole-body insulin sensitivity by hyperinsulinemic euglycemic clamps. Plasma levels of C-reactive protein and interleukin-6 decreased significantly with etanercept (C-reactive protein from 9.9 ± 3.1 to 4.8 ± 1.4 mg l–1, p = 0.04; interleukin-6 from 3.1 ± 0.4 to 1.9 ± 0.2 ng l–1, p = 0.03). Vasodilatory responses to serotonin and sodium nitroprusside infusions remained unchanged. Insulin effect on vasodilatation and on whole-body and forearm glucose uptake remained unchanged as well. β-Cell function tended to improve. Conclusion: Although short-term etanercept treatment had a significant beneficial effect on systemic inflammatory markers, no improvement of vascular or metabolic insulin sensitivity was observed.